{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:50Z","timestamp":1766514170682,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00228-021-03162-5","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T04:04:11Z","timestamp":1622520251000},"page":"971-978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia"],"prefix":"10.1007","volume":"77","author":[{"given":"Takahiro","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Uotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihoko","family":"Yamade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Hamaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moriya","family":"Iwaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2202-595X","authenticated-orcid":false,"given":"Takahisa","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"3162_CR1","doi-asserted-by":"crossref","unstructured":"Sontag SJ (1990) The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin N Am 19:683\u2013712","DOI":"10.1016\/S0889-8553(21)00664-6"},{"issue":"Suppl 1","key":"3162_CR2","first-page":"27","volume":"39","author":"EC Klinkenberg-Knol","year":"1992","unstructured":"Klinkenberg-Knol EC (1992) The role of omeprazole in healing and prevention of reflux disease. Hepatogastroenterology 39(Suppl 1):27\u201330","journal-title":"Hepatogastroenterology"},{"key":"3162_CR3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/j.1875-9114.1993.tb02689.x","volume":"13","author":"F Massoomi","year":"1993","unstructured":"Massoomi F, Savage J, Destache CJ (1993) Omeprazole: a comprehensive review. Pharmacotherapy 13:46\u201359","journal-title":"Pharmacotherapy"},{"key":"3162_CR4","unstructured":"Dobrilla G, Di Fede F (1339) Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. Clin Ther 15 Suppl B:2\u201313"},{"key":"3162_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1067\/mcp.2002.127637","volume":"72","author":"T Furuta","year":"2002","unstructured":"Furuta T, Shirai N, Watanabe F et al (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453\u2013460","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"3162_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000200917","volume":"51","author":"NJ Bell","year":"1992","unstructured":"Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH (1992) Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51(Suppl 1):59\u201367","journal-title":"Digestion"},{"key":"3162_CR7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1046\/j.1365-2036.1998.00419.x","volume":"12","author":"PO Katz","year":"1998","unstructured":"Katz PO, Anderson C, Khoury R, Castell DO (1998) Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 12:1231\u20131234","journal-title":"Aliment Pharmacol Ther"},{"key":"3162_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1572-0241.1998.221_a.x","volume":"93","author":"PL Peghini","year":"1998","unstructured":"Peghini PL, Katz PO, Bracy NA, Castell DO (1998) Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763\u2013767","journal-title":"Am J Gastroenterol"},{"key":"3162_CR9","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/apt.13588","volume":"43","author":"T Kagami","year":"2016","unstructured":"Kagami T, Sahara S, Ichikawa H et al (2016) Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 43:1048\u20131059","journal-title":"Aliment Pharmacol Ther"},{"key":"3162_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H et al (2015) Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2014a randomised open-label cross-over study. Aliment Pharmacol Ther 42:719\u2013730","journal-title":"Aliment Pharmacol Ther"},{"key":"3162_CR11","doi-asserted-by":"crossref","unstructured":"Cheng Y, Liu J, Tan X et al (2020) Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis. Dig Dis Sci","DOI":"10.1007\/s10620-020-06141-5"},{"key":"3162_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/apt.15641","volume":"51","author":"T Takeuchi","year":"2020","unstructured":"Takeuchi T, Furuta T, Fujiwara Y et al (2020) Randomised trial of acid inhibition by vonoprazan 10\/20 mg once daily vs rabeprazole 10\/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Aliment Pharmacol Ther 51:534\u2013543","journal-title":"Aliment Pharmacol Ther"},{"key":"3162_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/apt.12012","volume":"36","author":"CS Jianu","year":"2012","unstructured":"Jianu CS, Fossmark R, Viset T et al (2012) Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 36:644\u2013649","journal-title":"Aliment Pharmacol Ther"},{"key":"3162_CR14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s10620-015-4014-0","volume":"61","author":"N Nandy","year":"2016","unstructured":"Nandy N, Hanson JA, Strickland RG, McCarthy DM (2016) Solitary gastric carcinoid tumor associated with long-term use of omeprazole: a case report and review of the literature. Dig Dis Sci 61:708\u2013712","journal-title":"Dig Dis Sci"},{"key":"3162_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3109\/00365521.2011.627444","volume":"47","author":"CS Jianu","year":"2012","unstructured":"Jianu CS, Lange OJ, Viset T et al (2012) Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 47:64\u201367","journal-title":"Scand J Gastroenterol"},{"key":"3162_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/apm.12380","volume":"123","author":"R Fossmark","year":"2015","unstructured":"Fossmark R, Sagatun L, Nordrum IS, Sandvik AK, Waldum HL (2015) Hypergastrinemia is associated with adenocarcinomas in the gastric corpus and shorter patient survival. APMIS\u202f: acta pathologica, microbiologica, et immunologica Scandinavica 123:509\u2013514","journal-title":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica"},{"key":"3162_CR17","first-page":"70","volume":"97","author":"Y Kojima","year":"2018","unstructured":"Kojima Y, Takeuchi T, Sanomura M et al (2018) Does the novel potassium-competitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A multicenter prospective cross-sectional study Digestion 97:70\u201375","journal-title":"A multicenter prospective cross-sectional study Digestion"},{"key":"3162_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/00365521.2018.1450442","volume":"53","author":"HL Waldum","year":"2018","unstructured":"Waldum HL, S\u00f8rdal \u00d8, Fossmark R (2018) Proton pump inhibitors (PPIs) may cause gastric cancer\u2014clinical consequences. Scand J Gastroenterol 53:639\u2013642","journal-title":"Scand J Gastroenterol"},{"key":"3162_CR19","doi-asserted-by":"crossref","unstructured":"Ashida K, Sakurai Y, Hori T, et al (2016) Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 43:240\u201351","DOI":"10.1111\/apt.13461"},{"key":"3162_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.clpt.2004.10.010","volume":"77","author":"M Sugimoto","year":"2005","unstructured":"Sugimoto M, Furuta T, Shirai N et al (2005) Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin Pharmacol Ther 77:302\u2013311","journal-title":"Clin Pharmacol Ther"},{"key":"3162_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1046\/j.1365-2036.2000.00799.x","volume":"14","author":"T Katsube","year":"2000","unstructured":"Katsube T, Adachi K, Kawamura A et al (2000) Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 14:1049\u20131056","journal-title":"Aliment Pharmacol Ther"},{"key":"3162_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1046\/j.1365-2036.2001.01050.x","volume":"15","author":"S Xue","year":"2001","unstructured":"Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO (2001) Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 15:1351\u20131356","journal-title":"Aliment Pharmacol Ther"},{"key":"3162_CR23","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1111\/j.1440-1746.2006.04721.x","volume":"22","author":"T Ichikawa","year":"2007","unstructured":"Ichikawa T, Ota H, Sugiyama A et al (2007) Effects of a novel histamine H2-receptor antagonist, lafutidine, on the mucus barrier of human gastric mucosa. J Gastroenterol Hepatol 22:1800\u20131805","journal-title":"J Gastroenterol Hepatol"},{"key":"3162_CR24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejphar.2011.02.007","volume":"658","author":"M Nakano","year":"2011","unstructured":"Nakano M, Kitano S, Nanri M, Kiniwa M (2011) Lafutidine, a unique histamine H2-receptor antagonist, inhibits distention-induced gastric acid secretion through an H2 receptor-independent mechanism. Eur J Pharmacol 658:236\u2013241","journal-title":"Eur J Pharmacol"},{"key":"3162_CR25","first-page":"79","volume":"68","author":"T Sano","year":"2017","unstructured":"Sano T, Utsumi D, Amagase K et al (2017) Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons. Journal of physiology and pharmacology\u202f: an official journal of the Polish Physiological Society 68:79\u201390","journal-title":"Journal of physiology and pharmacology : an official journal of the Polish Physiological Society"},{"key":"3162_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1248\/bpb.25.379","volume":"25","author":"H Itoh","year":"2002","unstructured":"Itoh H, Naito T, Takeyama M (2002) Lafutidine changes levels of somatostatin, calcitonin gene-related peptide, and secretin in human plasma. Biol Pharm Bull 25:379\u2013382","journal-title":"Biol Pharm Bull"},{"key":"3162_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00228-017-2324-1","volume":"74","author":"T Suzuki","year":"2018","unstructured":"Suzuki T, Kagami T, Uotani T et al (2018) Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin. Eur J Clin Pharmacol 74:45\u201352","journal-title":"Eur J Clin Pharmacol"},{"key":"3162_CR28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3109\/00365527909181399","volume":"14","author":"R Stockbr\u00fcgger","year":"1979","unstructured":"Stockbr\u00fcgger R, Jaup B, Hammer R, Dotevall G (1979) Inhibition of gastric acid secretion by pirenzepine (LS 519) in man. Scand J Gastroenterol 14:615\u2013620","journal-title":"Scand J Gastroenterol"},{"key":"3162_CR29","doi-asserted-by":"crossref","unstructured":"Carmine AA, Brogden RN (1985) Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs 30:85\u2013126","DOI":"10.2165\/00003495-198530020-00001"},{"key":"3162_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/BF03348181","volume":"10","author":"M Del Tacca","year":"1987","unstructured":"Del Tacca M, Soldani G, Polloni A, Bernardini C, Costa F, Bellini M (1987) The effects of the antimuscarinic drugs pirenzepine and atropine on plasma portal levels of somatostatin and gastrin in the dog. J Endocrinol Invest 10:507\u2013511","journal-title":"J Endocrinol Invest"},{"key":"3162_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF02389513","volume":"31","author":"A Tari","year":"1996","unstructured":"Tari A, Hamada M, Kamiyasu T et al (1996) Effects of pirenzepine on omeprazole-induced hypergastrinemia and acid suppression in peptic ulcer patients. J Gastroenterol 31:167\u2013170","journal-title":"J Gastroenterol"},{"key":"3162_CR32","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A et al (2015) Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 41:636\u2013648","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 7","key":"3162_CR33","first-page":"77","volume":"29","author":"KC Lloyd","year":"1994","unstructured":"Lloyd KC, Soll AH (1994) Multiple pathways controlling acid secretion. J Gastroenterol 29(Suppl 7):77\u201379","journal-title":"J Gastroenterol"},{"key":"3162_CR34","doi-asserted-by":"crossref","unstructured":"Makhlouf GM, Schubert ML (1990) Gastric somatostatin: a paracrine regulator of acid secretion. Metabolism: clinical and experimental 39:138\u201342","DOI":"10.1016\/0026-0495(90)90232-2"},{"key":"3162_CR35","first-page":"G184","volume":"248","author":"R Sue","year":"1985","unstructured":"Sue R, Toomey ML, Todisco A, Soll AH, Yamada T (1985) Pirenzepine-sensitive muscarinic receptors regulate gastric somatostatin and gastrin. Am J Physiol 248:G184\u2013G187","journal-title":"Am J Physiol"},{"key":"3162_CR36","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/apt.12090","volume":"36","author":"R Fossmark","year":"2012","unstructured":"Fossmark R, S\u00f8rdal \u00d8, Jianu CS et al (2012) Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther 36:1067\u20131075","journal-title":"Aliment Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03162-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03162-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03162-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T10:36:09Z","timestamp":1699094169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03162-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["3162"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03162-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"assertion":[{"value":"25 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}